Cranbury, NJ - VaxInnate Corporation, a biotech firm, announced recently that it has named a new chief scientific officer, among several appointments, as it aims to drive pipeline growth, according to Eric Strauss of NJBIz.
Lynda Tussey, vice president of research and development, has been promoted to the role as the company reprioritizes its research and development resources to advance initiatives outside its lead influenza vaccine candidates, it said in a news release.
“Dr. Tussey has been an invaluable asset during her time at VaxInnate, with a deep background in immune modulation that she has applied to our proprietary vaccine programs,” Wayne F. Pisano, CEO and president, said in a prepared statement. “In her new role as chief scientific officer, she will be responsible for developing the long-term clinical growth plan to enrich the company’s pipeline while also devoting resources to our ongoing influenza, dengue and (Clostridium difficile) programs, and leading VaxInnate’s discovery efforts.”
For the full story: http://www.njbiz.com/article/20150520/NJBIZ01/150529974/cranbury-biotech-company-names-chief-scientific-officer
“Dr. Tussey has been an invaluable asset during her time at VaxInnate, with a deep background in immune modulation that she has applied to our proprietary vaccine programs,” Wayne F. Pisano, CEO and president, said in a prepared statement. “In her new role as chief scientific officer, she will be responsible for developing the long-term clinical growth plan to enrich the company’s pipeline while also devoting resources to our ongoing influenza, dengue and (Clostridium difficile) programs, and leading VaxInnate’s discovery efforts.”
For the full story: http://www.njbiz.com/article/20150520/NJBIZ01/150529974/cranbury-biotech-company-names-chief-scientific-officer
